Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

This study tests a combination of two targeted cancer drugs — vebreltinib and furmonertinib — in people with advanced lung cancer (non-small cell lung cancer, NSCLC) whose tumors have specific gene mutations. These patients have already tried standard targeted therapy that stopped working. **You may be eligible if...** - You are 18 or older - You have been diagnosed with advanced or metastatic NSCLC (stage IIIB, IIIC, or IV) - Your tumor has a specific EGFR mutation (exon 19 deletion or L858R) - Your cancer progressed after treatment with an EGFR-targeting drug (like osimertinib) - Your tumor shows c-Met amplification confirmed by testing - You have at least one measurable tumor lesion **You may NOT be eligible if...** - You have received certain prior treatments (e.g., c-Met inhibitors) - You have uncontrolled brain metastases - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.